Introduction
============

Cholangiocarcinoma, an aggressive malignant tumor that develops from the bile duct epithelium, is associated with local invasiveness and a high rate of metastasis ([@b1-ol-08-03-0993],[@b2-ol-08-03-0993]). The worldwide incidence and mortality rates associated with cholangiocarcinoma have risen over the past three decades. In Thailand, the annual incidence of cholangiocarcinoma is 87 per 100,000 inhabitants ([@b3-ol-08-03-0993]). In the United States, the most commonly recognized risk factor for cholangiocarcinoma is primary sclerosing cholangitis ([@b4-ol-08-03-0993]). However, in Southeast Asia and particularly in Thailand, infection with hepatobiliary flukes (*Opisthorchis viverrini*) is the most common risk factor for cholangiocarcinoma ([@b5-ol-08-03-0993]). Therapeutic options for cholangiocarcinoma patients are limited, as this type of cancer responds poorly to chemotherapy and radiation therapy. Surgery is thus the only potentially effective treatment for cholangiocarcinoma. However, typical five-year survival rates of 32--50% are achieved only by a small number of patients with negative histological margins at the time of surgery ([@b6-ol-08-03-0993]--[@b8-ol-08-03-0993]). Therefore, the understanding of the mechanisms involved in cancer cell invasion and metastasis may be useful in developing new therapeutic options for cholangiocarcinoma patients.

The function of the extracellular matrix (ECM) in the tumor microenvironment is not limited to forming a barrier against tumor invasion. Previous studies have indicated that interactions between cancer cells and the ECM play an important role in cancer progression. The molecular components of the ECM, such as fibronectin, laminin, collagen and heparin sulfate proteoglycans, communicate with cancer cells and modulate a variety of cellular functions required for cancer cells to exhibit invasive and metastatic properties ([@b9-ol-08-03-0993]--[@b11-ol-08-03-0993]). Numerous results from pathological studies have indicated that cholangiocarcinoma cells are surrounded by a dense sheath of connective tissue that contains the ECM ([@b12-ol-08-03-0993]--[@b14-ol-08-03-0993]). However, there have been no studies to date regarding the definitive role that the ECM plays in cholangiocarcinoma cell invasion. Therefore, we aimed to investigate the involvement of the ECM in cholangiocarcinoma cell invasion.

Materials and methods
=====================

Cell cultures
-------------

The RMCCA1 human cholangiocarcinoma cell line, originally derived from a cholangiocarcinoma patient ([@b15-ol-08-03-0993]), was grown in Ham's F12 medium (Gibco, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (Gibco) at 37°C in a 5% CO~2~ humidified atmosphere.

Cell invasion assay
-------------------

To study the mechanism of cancer cell invasion *in vitro*, RMCCA1 cells were cultured in BD Matrigel matrix (BD Biosciences, Bedford, MA, USA) for 0--24 h. Next, cancer cells were seeded into porous cell culture insert cups (BD Biosciences) each containing a layer of matrix gel. The number of cancer cells that invaded through the basement membrane within 24 h was assessed by staining the cells with crystal violet (Sigma-Aldric, St. Louis, MO, USA) ([@b16-ol-08-03-0993]).

Two-dimensional (2D) gel electrophoresis
----------------------------------------

2D gel electrophoresis was performed for the analysis of proteins extracted from cholangiocarcinoma cells cultured in uncoated and 24-h matrix gel-coated plates. Each electrophoresis gel contained three pooled samples from the cell culture plates. Six gels were prepared in biological triplicates from the uncoated and matrix gel-coated plates. Protein samples (500 μg) were applied to 18-cm immobilized pH gradient (IPG) gel strips (pH 3--10; GE Healthcare, Uppsala, Sweden) by cup loading near the anodic ends of the strips. Isoelectric focusing (IEF) was performed using an Ettan IPGphor Manifold on an Ettan IPGphor isoelectric focusing unit (GE Healthcare) for 32,000 Vh at 20°C. Following IEF, each gel strip was equilibrated with equilibration buffer. The IPG strips were then loaded and run on 12.5% acrylamide gels (GE Healthcare) using the Ettan DALTsix electrophoresis system (GE Healthcare). The run was stopped after the bromophenol blue dye front had run off the bottom of the gels. The gels were then stained with colloidal Coomassie Blue (GE Healthcare).

2D image analysis
-----------------

The proteins were visualized using an ImageScanner (GE Healthcare). The gel images were analyzed to determine differential protein expression profiles using ImageMaster 2D Platinum software (GE Healthcare). Student's t-test was used for statistical analysis and P\<0.05 was considered to indicate a statistically significant difference.

Protein identification by liquid chromatography-tandem mass spectrometry (LC-MS/MS)
-----------------------------------------------------------------------------------

### In-gel digestion

LC-MS/MS was performed by the Proteomics Laboratory, Genome Institute, National Science and Technology Development Agency (Pathumthani, Thailand). Following 2D analysis, an in-gel digestion was performed. Briefly, after the protein spots were excised, the gel plugs were dehydrated with 100% acetonitrile (ACN), reduced with 10 mM DTT in 10 mM ammonium bicarbonate at room temperature for 1 h and alkylated at room temperature for 1 h in the dark in the presence of 100 mM iodoacetamide in 10 mM ammonium bicarbonate. Following alkylation, the gel pieces were dehydrated twice with 100% ACN for 5 min. For the in-gel digestion of the proteins, 10 μl trypsin solution (20 ng/μl trypsin in 50% ACN/10 mM ammonium bicarbonate) was added to the gels followed by incubation at room temperature for 20 min. Next, 20 μl 30% ACN was added to keep the gels immersed throughout digestion. The gels were incubated at 37°C overnight. To extract the peptide digestion products, 30 μl 50% ACN in 0.1% formic acid was added to the gels, which were then incubated at room temperature for 10 min in a shaker. The extracted peptides were collected and pooled in a new tube. The pooled extracted peptides were dried by vacuum centrifugation at 2,500 × g for 10 min and stored at −80°C until further mass spectrometric analysis.

### LC-MS/MS analysis

The LC-MS/MS analysis of the digested peptide mixtures was performed using a Waters SYNAPT™ HDMS™ system (Waters, Milford, MA, USA). The 1D-nanoLC was performed with a Waters nanoACQUITY UPLC system (Waters). Tryptic digests (4 μl) were injected onto an reversed-phase analytical column (20 cm × 75 μm) packed with 1.7-μm ethylene bridged hybrid C18 material (Waters). The peptides were eluted with a linear gradient of 2--40% acetonitrile developed over 30 min at a flow rate of 1000 nl/min. This elution was followed by a 10-min 80% acetonitrile treatment to clean the column before using 2% acetonitrile for the next sample. The effluent samples were electrosprayed into a mass spectrometer (SYNAPT HDMS system) for MS/MS analysis of the peptides, and spectral data were generated for further protein identification by matching against hits in a database search.

Mass lists in the form of Mascot generic files were created and used as the inputs for the Mascot MS/MS Ion web-based search functionality at the National Center for Biotechnology Information non-redundant database ([www.matrixscience.com](www.matrixscience.com)). The default search parameters were applied as follows: Enzyme, trypsin; taxonomy, *Homo sapiens* (human); maximum missed cleavages, 1; fixed modifications, carbamidomethyl (C); variable modifications, oxidation (M); peptide tolerance, ±1.2 Da; MS/MS tolerance, ±0.6 Da; peptide charge, 1+, 2+ and 3+; and instrument, ESI-QUAD-TOF.

### Western blot analysis

Protein extracts isolated from the cells cultured in the uncoated and 24-h matrix gel-coated plates were separated by 12% SDS-PAGE and then transferred onto a nitrocellulose membrane (GE Healthcare). The membrane was subsequently incubated with monoclonal antibodies against L-plastin (1:50; Santa Cruz Biotechnology, Santa Cruz, CA, USA) and β-actin (1:500; Cell Signaling Technology, Danvers, MA, USA). Horseradish peroxidase-conjugated anti-mouse immunoglobulin G (IgG) and anti-rabbit IgG at 1:5,000 dilutions were used as secondary antibodies (GE Healthcare). The blots were visualized using an ECL Plus detection kit and Hyperfilm ECL (GE Healthcare). The western blot results were quantified using densitometer and image analysis software (ImageScanner III and ImageQuant TL; GE Healthcare, Uppsala, Sweden).

### Inhibition of L-plastin expression using transient siRNA transfection

L-plastin siRNA (Santa Cruz Biotechnology) was used to knock down L-plastin gene expression. A fluorescein-labeled, double-stranded RNA duplex (BLOCK-iT™ Fluorescent Oligo; Invitrogen, Melville, NY, USA) was designed as a control. The siRNA molecules were diluted in Opti-MEM^®^ I Medium without serum (Gibco) and mixed gently. Next, Lipofectamine™ 2000 (Invitrogen) was diluted in Opti-MEM I Medium without serum, mixed gently and incubated for 5 min at room temperature. The diluted siRNA molecules and diluted Lipofectamine 2000 were then combined. The mixtures were incubated for 20 min at room temperature to allow for complex formation to occur. The siRNA molecule-Lipofectamine 2000 complexes were added to each well containing cells and medium, and mixed gently by rocking the plate back and forth. The cells were incubated at 37°C in a CO~2~ incubator for 6 h. Next, the growth medium was replaced after 6 h, and the cells were harvested 24 h after transfection. Western blotting analysis using the L-plastin antibody was performed to assess the degree of L-plastin gene expression knockdown.

### Immunofluorescence microscopy

Cells (5×10^4^) were incubated with the primary antibody, anti-L-Plastin (1:10), for 1 h at room temperature. The cells were then washed and incubated with the appropriate secondary antibody (Alexa Fluor 594, anti-mouse; Molecular Probes, Grand Island, NY, USA) for 1 h at room temperature. The actin filaments (F-actin) in the cell cytoplasm were stained with Alexa Fluor 488 phalloidin (Molecular Probes), and the nuclei were stained with TOPO3 (Molecular Probes). The cover slides were removed from the plates and mounted with antifade on the slides. Cell images were captured with a confocal scanning biological microscope (FV1000; Olympus, Tokyo, Japan).

### Immunohistochemical staining

The study was performed with approval from the Ethics Committee of Rajavithi Hospital (Bangkok, Thailand). Paraffinized sections on glass slides were subjected to L-plastin detection by standard immunohistochemical technique. Sections were hybridized overnight at 4°C with a 1:50 dilution of L-plastin antibody (Abcam, Cambridge, MA, USA), followed by incubation with the secondary antibody, polyclonal Goat Anti-Mouse IgG (Abcam), conjugated to horseradish peroxidase that catalyzes a color-producing reaction (Abcam). The signals were visualized under high power magnification (x200) on an Olympus BH2 microscope.

### Statistical analysis

Continuous values for the observed levels in the invasion assay were expressed as the mean and standard deviation. One-way analysis of variance was used for the analysis of the multiple variables of the cell invasion assay. Student's t-test was employed to evaluate the mean differences in the intensity volume of each corresponding spot between the two groups of samples. The statistical analysis of the immunohistochemical studies was performed using either the χ^2^ test or Fisher's exact test. P\<0.05 was considered to indicate a statistically significant difference.

Results
=======

Culturing cholangiocarcinoma cells in matrix gel increases their invasiveness
-----------------------------------------------------------------------------

RMCCA1 cholangiocarcinoma cells were incubated in matrix gel for 0--24 h, and invasion assays were then performed. The results showed that a significantly higher number of cholangiocarcinoma cells that were cultured in matrix gel invaded through the insertion cup compared with that observed with the cells that were cultured on uncoated plates (P\<0.001; [Fig. 1](#f1-ol-08-03-0993){ref-type="fig"}).

Proteomic study of cholangiocarcinoma cells cultured in matrix gel
------------------------------------------------------------------

To investigate the proteins potentially involved in cholangiocarcinoma cell invasion, cholangiocarcinoma cells were cultured in plates coated with or without matrix gel. Next, 2D gel electrophoresis using pH 3--10 Linear IPG strips was performed to identify the protein expression profiles of these cells. Approximately 800 protein spots were detected by colloidal Coomassie staining. Quantitative intensity and statistical analyses identified 129 protein spots with significantly altered expression levels in matrix gel culture compared with the uncoated culture system. Of these 129 proteins, 60 proteins exhibited greater than two-fold upregulation as determined by mass spectrometry. All the identified proteins were in the expected ranges of their theoretical molecular masses and pI values ([Table I](#tI-ol-08-03-0993){ref-type="table"}). We report for the first time that the ECM plays a major role in the regulation of cholangiocarcinoma cell invasion. Based on 2D electrophoresis results, we identified the proteins that were upregulated when cholangiocarcinoma cells were cultured in matrix gel for 24 h.

Functional studies of protein expression in cholangiocarcinoma cells cultured in matrix gel
-------------------------------------------------------------------------------------------

The identified proteins that exhibited significant changes in expression levels were classified using a UniProtKB search for protein functional analysis in the species *Homo sapiens* (human). Based on the search results, these proteins are involved in energy metabolism, molecular chaperoning, cytoskeleton functions, actin binding, translation, transcription regulation, calcium ion binding, cell structure and signal transduction ([Fig. 2A](#f2-ol-08-03-0993){ref-type="fig"}). Contact with the ECM and the remodeling of the actin cytoskeleton can drive cancer cell motility and promote invasion. L-plastin is one of the actin-binding proteins that exhibited a high level of protein expression in cholangiocarcinoma cells cultured in matrix gel. We performed a western blot analysis to confirm the results of the proteomic study. The results showed that a high level of L-plastin expression was identified in RMCCA1 cells cultured in matrix gel ([Fig. 2B](#f2-ol-08-03-0993){ref-type="fig"}). A previous study demonstrated that L-plastin localizes to actin-rich membrane structures involved in locomotion, adhesion and immune defense, thereby implying that L-plastin is involved in the organization of the actin cytoskeleton ([@b17-ol-08-03-0993]). In addition, L-plastin has also been detected in solid tumors of epithelial and mesenchymal origin and has been suggested to be involved in cancer cell invasion ([@b18-ol-08-03-0993]). In line with these observations, we found that the number of cholangiocarcinoma cell invasion events significantly decreased when the expression of L-plastin was inhibited with L-plastin siRNA.

Effect of L-plastin on cholangiocarcinoma cell invasion
-------------------------------------------------------

To determine whether the expression of L-plastin is associated with cholangiocarcinoma cell invasion, we knocked down the expression of L-plastin using L-plastin siRNA. The western blot ([Fig. 3A](#f3-ol-08-03-0993){ref-type="fig"}) and immunofluorescence studies ([Fig. 3B](#f3-ol-08-03-0993){ref-type="fig"}) demonstrated that L-plastin was significantly downregulated after transfecting the RMCCA1 cells with L-plastin siRNA. Moreover, the invasion assay showed that the number of cancer cell invasion events was significantly decreased with the L-plastin siRNA cells compared with those treated with the control dsRNA (P\<0.001; [Fig. 3C](#f3-ol-08-03-0993){ref-type="fig"}).

Detection of L-plastin expression in paraffin-embedded cholangiocarcinoma specimens
-----------------------------------------------------------------------------------

The expression of L-plastin was determined by immunohistochemistry in 24 paraffin-embedded cholangiocarcinoma specimens. In these cancerous tissues, L-plastin-specific signals were localized mainly in the nucleus and cytoplasm of cholangiocarcinoma cells that invaded the basement membrane and presented as mesenchymal-like cells ([Fig. 4](#f4-ol-08-03-0993){ref-type="fig"}). However, cholangiocarcinoma cells that were arranged in a granular structure were negative for L-plastin.

We found that 37.5% (9/24) of the cholangiocarcinoma specimens were positive for the L-plastin expression signal. The correlation between the expression of L-plastin and the clinical characteristics is shown in [Table II](#tII-ol-08-03-0993){ref-type="table"}. The expression of L-plastin in cholangiocarcinoma was detected in all stages of the disease.

Discussion
==========

We report for the first time that the ECM plays a major role in the regulation of cholangiocarcinoma cell invasion. Based on 2D electrophoresis results, we identified the proteins that were upregulated when cholangiocarcinoma cells were cultured in matrix gel for 24 h. L-plastin, a major F-actin-bundling protein, was significantly upregulated in matrix-gel-coated plates compared with uncoated plates. The results were confirmed by western blotting, as L-plastin exhibited higher expression levels in RMCCA1 cells cultured in matrix-coated plates. A previous study demonstrated that L-plastin localizes to actin-rich membrane structures involved in locomotion, adhesion and immune defense, thereby implying that L-plastin is involved in the organization of the actin cytoskeleton ([@b17-ol-08-03-0993]). In addition, L-plastin has also been detected in solid tumors of epithelial and mesenchymal origin and has been suggested to play a role in cancer cell invasion ([@b18-ol-08-03-0993]). In line with these observations, we found that the number of cholangiocarcinoma cell invasion events significantly decreased when the expression of L-plastin was inhibited with L-plastin siRNA.

Confirming the results of prior studies, we observed that L-plastin is located in the nuclei and cytoplasm of cancer cells ([@b17-ol-08-03-0993],[@b19-ol-08-03-0993]). The functional relevance of the nucleocytoplasmic shuttling of L-plastin currently remains unclear. L-plastin may be involved in the regulation of nuclear actin, which is an essential component of the pre-initiation complex and cooperates with polymerases I, II and III in the regulation of gene expression ([@b20-ol-08-03-0993]). The formation of protrusive structures is driven by spatially and temporally regulated actin polymerization at the leading edge of the cell ([@b21-ol-08-03-0993]). Further studies should be performed to elucidate the involvement of L-plastin localization in cholangiocarcinoma cells. We found that L-plastin was primarily expressed in mesenchymal-like cholangiocarcinoma cells. These findings suggest that L-plastin expression is associated with the epithelial-mesenchymal transition of cholangiocarcinoma cells.

To understand whether our *in vitro* findings are also relevant *in vivo*, we performed immunohistochemical analyses of tumor specimens derived from cholangiocarcinoma patients. Our analyses demonstrated that L-plastin is expressed in cholangiocarcinoma specimens. However, the level of expression was not significantly correlated with tumor differentiation, lymph node or metastatic status. This finding is in contrast to that reported for colorectal cancer, in which the expression of L-plastin is significantly correlated with cancer staging ([@b22-ol-08-03-0993]). Variations in the biological features of the tumors and the limited number of specimens in our study may account for these differences. In conclusion, attachment to the ECM promotes cholangiocarcinoma cell progression by inducing L-plastin expression. Understanding this mechanism may help to identify a novel molecular target for the development of an effective therapy for cholangiocarcinoma patients.
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![RMCCA1 cholangiocarcinoma cell invasion assays. (A) Box plots comparing the number of cholangiocarcinoma cell invasion events in cells cultured in matrix gel and controls (^\*^P\<0.001 by analysis of variance, compared with the control). (B) Micrographs of cholangiocarcinoma cell invasion (cholangiocarcinoma cells were cultured in matrix gel for 0, 6, 12, 18 or 24 h before the invasion assays were performed). The scale bar indicates 100 μm (magnification, ×10).](OL-08-03-0993-g00){#f1-ol-08-03-0993}

![Protein functional analysis in cholangiocarcinoma cells cultured in matrix gel. (A) Functional classification of the differentially expressed proteins in cholangiocarcinoma cells cultured with matrix gel. The altered levels of protein expression were identified by mass spectrometric analysis (see [Table I](#tI-ol-08-03-0993){ref-type="table"}) and categorized according to protein function. Note that the spots with the same identities were counted as only one spot, and each number represents the percentage among the total number of proteins identified. (B) The expression levels of L-plastin in RMCCA1 cells following culture in matrix gel for 24 h were determined by western blot analysis. β-actin was used as a loading control.](OL-08-03-0993-g01){#f2-ol-08-03-0993}

![Effect of L-plastin on cholangiocarcinoma cell invasion. (A) The expression levels of L-plastin and β-actin in RMCCA1 cells transfected with either control dsRNA or L-plastin siRNA were determined by western blotting. Lane 1 represents protein extracted from RMCCA1 cells treated with control dsRNA, and lane 2 represents protein extracted from RMCCA1 cells treated with L-plastin siRNA. (B) Immunofluorescence detection by confocal microscopy. The cells were transfected with either control dsRNA or L-plastin siRNA. The cells were then triple-stained with monoclonal L-plastin antibody (red), phalloidin (green, to reveal filamentous actin) or TOPO3 (blue, to reveal the nucleus). The scale bar indicates 10 μm. (C) Box plots comparing the number of cholangiocarcinoma cell invasion events in cholangiocarcinoma cells treated with the control (dsRNA) and L-plastin siRNA (^\*^P\<0.001 by analysis of variance, compared with the control).](OL-08-03-0993-g02){#f3-ol-08-03-0993}

![Expression of L-plastin was shown in cholangiocarcinoma specimens by immunohistochemical staining. L-plastin was mainly localized within the nucleus. (A) Negative L-plastin staining; (B) positive L-plastin staining in the nuclei of tumor cells; and (C) positive L-plastin staining in the cytoplasm of tumor cells. The scale bar indicates 100 μm (magnification, ×200).](OL-08-03-0993-g03){#f4-ol-08-03-0993}

###### 

A summary of upregulated proteins expressed in cholangiocarcinoma cells cultured in matrix gel, as identified by Q-TOF MS and MS/MS analyses.

  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Functional category and protein name                         GI number   Mr        pI     Score   Coverage %   Ratio   Gene ID                    Cellular component
  ------------------------------------------------------------ ----------- --------- ------ ------- ------------ ------- -------------------------- ------------------------------------------------------------------
  Actin-binding protein                                                                                                                             

   L-plastin                                                   62087548    56,196    5.21   52      6            4.6     LCP1, PLS2                 Cytoplasm, cell membrane, cytoskeleton

   Cytovillin 2 (Ezrin)                                        340217      68,233    5.80   335     13           3.9     VIL2, EZR                  Cytoplasm, cell membrane, cytoskeleton

   ARP3 actin-related protein 3 homolog                        5031573     47,797    5.61   150     6            3.5     ACTR3                      Cytoskeleton

   α-actinin-4                                                 2804273     102,661   5.27   72      2            3.0     ACTN4                      Cytoplasm, nucleus

   Adenylyl cyclase-1 associated protein                       116241280   52,222    8.27   54      10           2.6     CAP1                       Cell membrane

   Fascin                                                      4507115     55,123    6.84   160     19           2.5     FSCN1                      Cytoplasm, cytoskeleton

   Cofilin-1                                                   5031635     18,719    8.22   129     17           2.3     CFL1                       Cytoplasm, nucleus, cell membrane, cytoskeleton

  Energy metabolism                                                                                                                                 

   Pyruvate Kinase (Pkm2)                                      67464392    60,277    8.22   166     20           7.3     PKM2                       Cytoplasm, nucleus

   Phosphoglycerate kinase 1                                   4505763     44,985    8.30   439     20           6.3     PGK1, PGKA                 Cytoplasm

   Aldolase A                                                  28614       39,706    8.34   267     11           3.5     ALDOA, ALDA                Cytoplasm, nucleus

   α-enolase (phosphopyruvatehydratase)                        693933      47,421    7.01   148     22           2.4     ENO1                       Cytoplasm, nucleus

   L-lactate dehydrogenase A chain                             126047      36,950    8.44   85      18           2.3     LDHA, PIG19                Cytoplasm

   ATP synthase, H^+^ transporting, mitochondrial F1 complex   4757810     59,828    9.16   182     17           13.5    ATP5A1, ATP5F1             Mitochondrion, Mitochondrion inner membrane

   Dihydrolipoamidesuccinyl transferase                        643589      48,896    8.90   165     7            3.8     DLST                       Mitochondrion

   Citrate synthase                                            33337556    51,942    8.45   169     5            3.4     CS                         Mitochondrion

   Fumaratehydratase, mitochondrial                            182794      50,524    7.23   305     11           2.7     FH                         Mitochondrion, cytoplasm

   Glutamate dehydrogenase                                     4885281     61,701    7.66   197     16           3.9     GLUD1                      Mitochondrion

   Dihydrolipoamide dehydrogenase                              83753870    50,656    6.50   236     9            2.2     DLD                        Mitochondrion

   acyl-Coenzyme A dehydrogenase                               76496475    68,414    8.76   233     10           2.1     ACADVL                     Mitochondrion, mitochondrion inner membrane

   Transketolase                                               37267       68,435    7.90   102     16           2.8     TKT                        Cytoplasm, nucleus

  Molecular chaperone                                                                                                                               

   Tumor rejection antigen 1, Endoplasmin                      74755280    92,282    4.77   89      4            11.9    GRP94, TRA1, HSP90B1       Endoplasmic reticulum

   T-complex protein 1 subunit γ                               14124984    60,934    6.10   157     7            6.3     CCT3, CCTG                 Cytoplasm

   Heat shock protein HSP 90-α                                 154146191   85,006    4.94   163     5            5.2     HSP90AA1                   Cytoplasm

   Heat shock protein HSP 90-β                                 119602173   57,868    4.92   59      2            2.3     HSP90AB1                   Cytoplasm

   Stress-induced-phosphoprotein)\                             5803181     63,227    6.40   145     19           3.8     STIP1                      Cytoplasm, nucleus
  1 (Hsp70/Hsp90-organizing protein                                                                                                                 

   60 kDa heat shock protein                                   77702086    61,346    5.70   580     16           5.0     HSPD1, HSP60               Mitochondrion

   Heat shock protein                                          386785      70,110    5.42   404     10           4.4     HSPA1L                     Cytoplasm

   Heat shock 70 kDa protein 8                                 5729877     71,082    5.37   203     13           3.8     HSPA8                      Cytoplasm

   Stress-70 protein, mitochondrial                            21264428    73,920    5.87   70      6            3.7     HSPA9                      Mitochondrion

   78 kDa glucose-regulated protein                            386758      72,185    5.03   251     7            4.1     GRP78, HSPA5               Endoplasmic reticulum

   T-complex polypeptide 1                                     36796       60,869    6.03   197     9            4.0     TCP1                       Cytoplasm, cytoskeleton

   Nucleophosmin (nucleolarphosphoprotein B23, numatrin)       15214852    32,760    4.64   198     12           3.3     NPM1, NPM                  Cytoplasm, nucleus, cytoskeleton

   Calreticulin                                                4757900     48,283    4.29   109     12           2.3     CALR                       Cytoplasm, endoplasmic reticulum, extracellular matrix, secreted

  Structural molecule                                                                                                                               

   Tubulin, β, 2                                               5174735     50,255    4.79   282     14           3.8     TUBB2C, TUBB4B             Cytoplasm, cytoskeleton, microtubule

   α-tubulin                                                   37492       50,810    5.02   123     13           2.6     TUBA4A, TUBA1              Cytoplasm, cytoskeleton, microtubule

  Cytoskeleton function                                                                                                                             

   Keratin, type I cytoskeletal 17                             4557701     48,361    4.97   303     28           3.7     KRT17                      Cytoplasm, intermediate filament, keratin

   Keratin, type I cytoskeletal 18                             30311       47,305    5.27   558     28           3.5     KRT18, PIG46 CYK18         Cytoplasm, intermediate filament, keratin

   Keratin, type I cytoskeletal 19                             24234699    44,079    5.04   455     44           2.1     KRT19                      Intermediate filament, keratin

   Keratin, type II cytoskeletal 6A                            5031839     60,293    8.09   248     29           5.8     KRT6A                      Intermediate filament, keratin

   Keratin, type II cytoskeletal 2 epidermal                   908801      60,448    8.09   422     15           4.3     KRT2                       Intermediate filament, keratin

   Keratin, type II cytoskeletal 8                             181573      53,529    5.52   238     9            4.3     KRT8, CYK8                 Cytoplasm, Intermediate filament, keratin, nucleus

   Keratin, type II cytoskeletal 7                             12803727    51,444    5.42   287     36           3.5     KRT7                       Cytoplasm, intermediate filament, keratin

  Transcription regulation                                                                                                                          

   Far upstream element-binding protein 1                      17402900    67,690    7.18   111     4            4.1     FUBP1                      Nucleus

   ETS translocation variant 5                                 221042722   65,643    5.69   174     9            2.6     ERM                        Nucleus

  Translation                                                                                                                                       

   Ribosomal protein P0                                        4506667     34,423    5.71   193     14           3.5     RPLP0                      Cytoplasm, nucleus

   Tyrosyl-tRNAsynthetase                                      4507947     59,448    6.61   403     16           2.4     YARS                       Cytoplasm

   Heterogeneous nuclear ribonucleoprotein L                   11527777    64,617    8.49   173     6            3.9     HNRNPL, HNRPL, P/OKcl.14   Cytoplasm, nucleus

   Heterogeneous nuclear ribonucleoproteins A2/B1              4504447     36,041    8.67   188     13           3.2     HNRNPA2B1                  Cytoplasm, nucleus, spliceosome

   Heterogeneous nuclear ribonucleoprotein K                   460789      51,325    5.13   88      12           2.0     HNRNPK, HNRPK              Cytoplasm, nucleus, spliceosome

  Calcium ion binding protein                                                                                                                       

   Annexin A1                                                  4502101     38,918    6.57   124     26           3.9     ANXA1, ANX1, LPC1          Cytoplasm, nucleus, cell membrane

   Annexin A2                                                  56967118    36,634    8.32   210     13           2.1     ANXA2                      Basement membrane, extracellular matrix

  Signal transduction                                                                                                                               

   14-3-3 protein epsilon                                      5803225     29,326    4.63   136     26           2.5     YWHAE                      Cytoplasm

   14-3-3 protein β/α                                          4507949     28,179    4.76   315     23           2.2     YWHAB                      Cytoplasm

  Elongation factor                                                                                                                                 

   Elongation factor Tu                                        704416      49,851    7.70   229     19           3.9     TUFM                       Mitochondrion

  Proteasome regulatory                                                                                                                             

   26S proteasome non-ATPase regulatory subunit 12             4506221     53,270    7.53   127     6            3.3     PSMD12                     Proteasome, nucleus, cytoplasm

  GTPase activation                                                                                                                                 

   Human rab GDI                                               285975      51,088    5.94   347     15           3.3     RABGDIB                    Cytoplasm

  Chromatin regulator                                                                                                                               

   Protein arginine                                            20070220    73,322    5.88   43      1            3.2     PRMT5                      Cytoplasm, nucleus

  N-methyltransferase 5                                                                                                                             

  Glycan metabolism                                                                                                                                 

   Protein kinase C substrate 80K-H isoform 2                  48255891    60,110    4.34   51      8            2.6     PRKCSH                     Endoplasmic reticulum

  Protein disulfide isomerase                                                                                                                       

   Prolyl 4-hydroxylase, β polypeptide                         20070125    57,480    4.76   586     24           2.6     P4HB                       Endoplasmic reticulum

  Protease inhibitor                                                                                                                                

   Serine proteinase inhibitor                                 62898301    42,857    5.90   167     9            2.3     SERPIN                     Secreted
  --------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

###### 

Correlation between L-plastin expression and the clinicopathological features of cholangiocarcinoma patients.

                          L-plastin expression       
  ----------------------- ---------------------- --- ------
  Gender                                             
   Male                   8                      5   1.00
   Female                 7                      4   
  Tumor differentiation                              
   Well                   5                      3   1.00
   Moderate and poor      10                     6   
  Lymph node metastasis                              
   No                     5                      4   0.65
   Yes                    10                     5   
  Distant metastasis                                 
   No                     11                     6   1.00
   Yes                    4                      3   
